Abnormal function of platelets and role of angelica sinensis in patients with ulcerative colitis

Table 1 Changes of all observed parameters in patients with UC 24 h after admission (mean ± SD)

Group	n	PC (× 109/L)	GMP-140 (ug/L)	TXB2 (ng/L)	6-keto-PGF1a (ng/L)	1 min PAR (%)	VWF:Ag (%)
Normal control	30	158.2 ± 32.5	41.4 ± 10.2	68.4 ± 26.4	18.3 ± 6.8	38.6 ± 14.2	103.6 ± 23.7
Patients with UC	64	189.8 ± 68.3a	52.1 ± 17.8b	98.8 ± 55.4b	12.9 ± 8.2b	58.2 ± 21.5b	143.6 ± 52.7b
Remissive UC	25	173.7 ± 36.4c	48.4 ± 11.4ac	87.4 ± 32.7ac	14.5 ± 6.0a	47.8 ± 16.5ad	127.9 ± 46.1ac
Active UC	39	201.8 ± 48.6b	54.9 ± 13.2b	115.5 ± 46.8b	11.3 ± 6.4b	65.5 ± 19.2b	154.5 ± 48.9b

^aP < 0.05,

^bP < 0.01 vs normal control,

^cP < 0.05,

^dP < 0.01, vs active UC group.

Table 2 Effects of ASI on abnormal function of platelet in patients with UC (mean ± SD)

Group	n	PC(×109/L)	GMP-140 (ng/L)	TXB2 (ng/L)	6-keto-PGF1a (ng/L)	1 min PAR (%)	VWF:Ag (%)
Routine therapy
Before therapy	33	188.6 ± 38.5	52.3 ± 15.2	96.9 ± 38.1	13.9 ± 5.3	59.4 ± 14.7	149.1 ± 48.0
After therapy	31	179.3 ± 36.2c	48.8 ± 13.7c	87.7 ± 28.6c	16.2 ± 5.7c	53.1 ± 15.6c	137.3 ± 48.2c
ASI therapy
Before therapy	31	193.9 ± 41.4	51.1 ± 13.8	99.3 ± 33.1	12.7 ± 5.3	56.8 ± 17.2	139.5 ± 50.2
After therapy	30	171.3 ± 37.8a	37.0 ± 10.9b	70.2 ± 25.9b	16.4 ± 6.2c	45.3 ± 14.4b	102.4 ± 24.7b

^aP < 0.05,

^bP < 0.01,

^cP > 0.05 vs before therapy group.